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INTRODUCTION
Endometrial cancer is the most common gynaecological malignancy with relative good prognosis. The standard treatment modality for these patients is extra-fascial hysterectomy, bilateral salpingo-oophorectomy and bilateral lymphadenectomy. Radiation therapy (external beam radiotherapy, vaginal brachytherapy or combination of these two methods) applied after surgery has been added to improve local control in the pelvic region. Although most patients undergo hysterectomy without difficulty, some patients who suffer from concomitant medical problems (such as cardiovascular diseases, obesity, advanced age, etc.) may be unsuitable for major abdominal surgery. 1, 2) Although the results of radiotherapy alone are poorer compared to surgery, radiotherapy may be the best radical treatment option for these patients. These patients are often treated with a combination of external-beam radiotherapy (EBRT) and brachytherapy or brachytherapy alone. Very few results using curative radiotherapy have been reported so far. The majority of publications describe low-dose-rate (LDR) brachytherapy, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] with only a few reporting high-dose-rate (HDR) brachytherapy. [12] [13] [14] [15] [16] [17] [18] [19] [20] In this report we update our long-term follow-up results of the prospective study whose aim was to evaluate the efficacy of HDR brachytherapy in combination with EBRT in the treatment of medically inoperable endometrial cancer.
MATERIALS AND METHODS
Between 1995 and 1998, 29 patients with stages I-III medically inoperable carcinoma of endometrium and significant medical risks precluding surgery (Table 1) were treated with definitive irradiation (EBRT and intracavitary HDR brachytherapy). Cardiovascular diseases, chronic pulmonary diseases and morbid obesity accounted for the majority of the inoperable cases.
Patients were evaluated using general physical and pelvic examination, pelvic and abdominal ultrasound and CT, routine blood counts, blood chemistry profile, chest X-ray, cystoscopy and proctoscopy. Fractionation dilatation and curettage (D&C) was performed on all patients before the initiation of therapy. All patients had histologically confirmed endometrial carcinoma. All patients were staged according to the clinical classification proposed by the International Federation of Gynecology and Obstetrics in 1971.
21) Staging was based on physical examination, fractional curettage, chest X-ray, ultrasound, and CT. Table 2 shows patient characteristics.
The treatment included external beam radiotherapy and intracavitary HDR brachytherapy. All patients from the beginning received external beam therapy. External beam therapy was performed with cobalt unit (AGAT-S, Russia) with symmetrically opposed fields of the same axis covering the whole uterus, vagina, and the lymph node regions (the external, common, and internal iliac lymph nodes, and the obturator lymph nodes). None of the patients received irradiation of the para-aortic lymph nodes. The dose administered to the whole pelvis was 16 Gy. The fractionation was 2.0 Gy daily, five fractions per week. After EBRT of the whole pelvis, intrauterine HDR brachytherapy (AGAT-B3, Russia) was initiated. HDR brachytherapy was performed using a remote-controlled afterloading system with a 60 Co source. Five intrauterine HDR brachytherapy fractions of 10 Gy were performed at weekly intervals. On four days per week free from brachytherapy, EBRT of the pelvis was continued with split-field (midline shield) parametrial and regional lymph node boost (34 Gy). The fractionation was 2.0 Gy daily, 4 fractions per week. The total EBRT dose to the pelvic sidewalls was 50 Gy.
The intracavitary HDR brachytherapy was given for all patients using the three-channel intrauterine applicator described by Khachaturian R.E. et al.. 22) The computerised treatment planning system was not used at that time. The treatment was planned mannually. In order to form pearshape reference isodose that was adapted to the shape of the uterus, the dose was prescribed to the points A (the same points as those used in cervical cancer brachytherapy), points C (3 cm laterally from the tip of central applicator), and point D (1.3 cm above the tip of the central applicator in the uterine longitudinal axis). 23) Thus, our reference volume approximates the outline of the serosa of the uterus (Fig. 1 ). We applied 5 fractions of 10 Gy to points A, B, and C. After the insertion of the three-channel applicator into the uterine cavity, the orthogonal X-ray and ultrasound was performed on all patients. The ultrasound was used for measuring of the distances from the applicators to the surface of the uterus. The median distance from the tip of the central applicator to the central part of the fundus uteri was 1.4 cm (0.6-2.3 cm). The median distance from the tip of the central applicator to the left cornulum of the uterus was 2.7 cm (2.1-3.4 cm). The median distance from the tip of central applicator to the right cornulum of the uterus was 2.8 cm (2.0-3.6 cm). The median distance from the middle part of Initial hemoglobin level
the central applicator (between cervical os and tip) and the anterior external contour of the uterus was 1.5 cm (0.7-2.1 cm). The median distance from the middle part of the central applicator and the posterior external contour of the uterus was 1.4 cm (0.6-2.1 cm). The median brachytherapy fraction dose of the central part of the fundus uteri was 10 Gy (7-19 Gy), in the left cornulum of the uterus -11 Gy (8-21 Gy), in the right cornulum of the uterus -11 Gy (7-22 Gy), in the middle central part of anterior uterine wall -12 Gy (8-16 Gy), and in the middle central part of posterior uterine wall -11 Gy (8-15 Gy). The HDR brachytherapy dose was 50 Gy delivered in 5 fractions on a weekly schedule. Doses delivered to the rectum and bladder were measured by dosimetry based on orthogonal X rays with Foley catheter balloon or rectal tube identified by radiopaque material. Maximal rectal and bladder doses were limited to 6 Gy per each brachytherapy fraction or a total EBRT and brachytherapy dose of 70-75 Gy in order to minimize the risk of late toxicity. For tolerance dose concerning late effects, an α/β-ratio of 3 was used in the calculation of the equivalent dose in 2-Gy fractions (EQD2) to rectum and bladder. Maximal cumulative (EBRT and brachytherapy) rectal EQD2 was 77.8 Gy, and maximal cumulative bladder EQD was 86 Gy. None of the patients received vaginal irradiation. After the therapy, the patients were seen regularly at outpatient clinic and underwent clinical examinations every 3 months for the first 2 years and every 6 months thereafter. After the completion of treatment, patients were followed by means of history, physical examination, PAP smears, chest X-ray, abdominal and pelvic ultrasound. Suspicious vaginal bleeding and/or positive cytology and/or palpable abnormalities in the uterus or cervix were investigated further by pelvic CT scan, pipelle endometrial biopsy, and/or dilatation and curettage. Symptom-specific or site-specific imaging (X-ray, ultrasound or CT) was used to establish distant metastases. During radiotherapy, all side effects were registered. All late complications were noted and classified according to late effects on the normal tissue-subjective objective management analytic (LENT-SOMA) scale. 24) The dates of death and the cause of death were obtained from the records of Lithuanian Cancer Registry. The Kaplan-Meier method was used to calculate the survival rates. The log-rank test was used to assess the difference between survival curves. Because the studied population was a cohort with serious intercurrent diseases, we felt diseasespecific survival to be more appropriate to report than overall survival rates. If death was the result of a cause other than endometrial cancer, the patient was excluded from calculations of disease-specific survival (DSS). The survival estimates have been performed using procedures of the STATA (ver.7). The study was approved by the local ethical committee (approval number -BE-2-36).
RESULTS
At the time of this analysis (March, 2009), the median follow-up time was 4.6 years with a minimum of 2 years and a maximum of 12 years. The number of confirmed deaths was 23. Eight patients (28%) died from endometrial cancer, 1 patient died from small-cell lung cancer (3%), and 14 patients (48%) died from intercurrent diseases (cardiovascular disease -6 patients (21%), stroke -4 patients (14%), thromboembolism -2 patients (7%), hepatic cirrhosis -1 patient (3%), and aortic stenosis -1 patient (3%)). Six patients (21%) are alive without evidence of the disease.
The patients in this study were at significantly greater risk of dying of their intercurrent illnesses than from endometrial cancer. Overall survival (OS) at 5 and 10 years was 48.3% and 20.7%, respectively. Disease-specific survival (DSS) at 5 and 10 years was 73.5% and 67.9%, respectively (Fig. 2) .
To elucidate the effect of age, we grouped patients into groups of 75 years of age and younger, and those older than 75. The 10-year OS rate was 23.1% for patients aged 75 years or younger, and 18.8% -for those older than 75 years (p = 0.30). The 10-year DSS rate was 79.4% for patients 75 aged years or younger, and 60.6% -for patients older than 75 years (p = 0.42).
The 10-year OS rate was 20.7% for all stages, 35.7% for Stage I disease, 0% for Stage II, and 16.7% -for stage III disease. The difference between stages I and II was significant (p = 0.027), but the difference between stages II and III, and between stages I and III (p = 0.72; p = 0.087) was not. The 10-year DSS rate was 73.5% for all stages, 85.7% for Stage I disease, 71.4% for Stage II, and 16.7% -for stage III disease. The difference between stages I and III, stages II and III was significant (p = 0.001; p = 0.009), but the difference between stages IB and II (p = 0.9) was not. Patients were staged by the length of uterine sounding using FIGO clinical staging system. The 10-year DSS rate was 100% for IA tumours (length of the uterine cavity less than 8 cm), and The 10-year DSS rate was 81.1% for endometrioid adenocarcinomas, and 0% for other carcinomas (clear-cell, papillary-serous, adenosquamous, and undifferentiated) (p = 0.013). The 10-year DSS rate was 83% for Grade 1 and Grade 2 tumors, and 48.5% -for Grade 3 tumors (p = 0.039) (Fig. 3) .
Initial hemoglobin levels > 120 g/l were associated with a 23.8% 10-year OS and 80.8% 10-year DSS, compared to 12.5% OS and 58.4% DSS if the hemoglobin was ≤ 120 g/l (p = 0.05; p = 0.015).
A total of 8 patients (27.6%) experienced failure. Five patients (17.2%) failed locally (uterus, 1; uterus and parametrium, 4), and 3 patients (10.3%) failed distantly (abdominal carcinomatosis, 1; lung metastasis, 2). Among locally failed five patients, four were with stage III endometrial cancer. In these cases the tumour was spread beyond the uterus in the parametria. The dose coverage in the surface of the uterine body was good, but it was insufficient dose coverage outside the uterus in the parametria. We suspect that this might influence the treatment outcome. The dose coverage to the fifth locally failed endometrial cancer patient was good. No local failures were observed for stage I patients. Distant metastasis occurred in 2 patients (6.9%) with stage IB and in 1 patient (3.4%) with stage III. Seventy-five per cent of all failures were observed in patients with grade 3 tumors. Sixty percent of the all pelvic failures occurred within the first 2 years.
No significant procedure-related complications (pulmonary embolism, myocardial infarction, uterine perforation, infection, etc) were encountered during HDR brachytherapy. Acute toxicities were limited to Grade 1, which occurred in 2 patients (7%). Diarrhea and proctitis occurred in both of these patients. Late Grade 1-2 radiation complications were observed in 4 patients (13.8%). Two patients had proctitis, and the other 2 patients had cystitis. Severe radiation toxicity (grade 3 or 4) was not observed in any of treated patients.
DISCUSSION
Surgery is the treatment of choice for patients with endometrial carcinoma. Adjuvant radiotherapy and/or chemotherapy is typically offered to patients with adverse factors in order to decrease the risk of relapse. However, in a small percentage of patients with endometrial cancer and severe medical conditions that preclude surgery, radiation therapy becomes the only curative alternative. A comparison of survival between surgery and radiotherapy series has limited value. Patients treated with primary radiotherapy typically have a higher death rate from intercurrent disease, reflecting an older patient population with more severe medical problems. Thus, the majority of deaths in our study (48%) were due to intercurrent diseases. Although overall survival rate in surgically treated patients is superior compared to patients treated with radiotherapy alone, disease-specific survival may be comparable. 9, 11) In this study, the DSS rates of patients with stage I and II were similar to those reported from studies of surgically treated patients. 25) There is a long experience in performing intracavitary radium therapy for definitive treatment of endometrial cancer with considerable clinical results. Several nonrandomized studies have shown similar results when retrospectively comparing LDR brachytherapy with HDR brachytherapy in the treatment of inoperable endometrial cancer. 26) Although the number of patients in this study was small, the 5-and 10-year OS and DSS results in our series are comparable to the results of intracavitary radium therapy, lowdose-rate (LDR) afterloading techniques, and HDR brachytherapy (Table 3) .
A variety of methods exist to treat inoperable endometrial cancer with radiotherapy alone. The radiation method used in this study is different from those reported by others. The main difference is that HDR brachytherapy was adminis- 
2)
LDRB + EBRT 146 I-III 46.5 (10 y) 68 (10 y) 11.7
Rose PG et al.
9)
LDRB + EBRT 64 I-II 53 (5 y) -6
Chao CKS et al. Note: OS, overall survival; DSS, disease-specific survival; DFS, disease-free survival; LDRB, low dose-rate brachytherapy; HDRB, high dose-rate brachytherapy; EBRT, external beam radiation therapy.
tered during EBRT. Thus, the overall treatment time was shorter and the dose was more intense. The low uterine failure rate for stage I and II patients in this study shows that high combined radiation doses are sufficient for tumor destruction in the uterus. The findings of this study confirm the data from other studies indicating that higher tumor stage, lower grade, and unfavourable tumor morphologic type are associated with lower survival rates. In our series, as in the different series in literature, the survival rates differed depending on the clinical stage with higher rates for early stages. In this study we used 1971 version of the FIGO staging system, thus the estimation of the extent of the disease was relatively inaccurate. Inaccuracy in clinical staging may influence similar 10-year DSS results between stage IA and IB patients (p = 0.36).
There is a lack of data in literature regarding the results of primary radiation therapy of clinically inoperable stage III endometrial cancer. Ahmad K. et al. reported that in patients with stage III disease, the survival was 57.3% among patients who underwent combined treatment as compared to 17.5% among those receiving radiation therapy alone. 27) Our data shows unsatisfactory overall and disease-specific survival of these patients. Treatment of locally advanced endometrial cancer is generally directed towards the control of the disease in the pelvis. Primary radiotherapy may be sufficient in patients with stage I and II disease where in our series pelvic and distant failures occurred in 13.6% (3/22) of patients. The failure rate was, however, much higher in patients with stage III disease where failures in the pelvis and at distant sites occurred in 80% (4/5) of the patients. Despite high radiation doses delivered, three of five patients died from local recurrence, and one died from lung metastasis. Only one of these patients with stage III is alive without any evidence of the disease at 12 years follow-up.
There is much discussion in literature regarding the use of EBRT as adjunct to brachytherapy. The rationale for adding EBRT is that nearly 20% of clinical stage I patients have extrauterine disease -especially in grade 3 tumours.
28) The addition of EBRT to brachytherapy may improve the outcome, as some studies suggest. 3, 6) In our study, EBRT was used to increase the dose to the outer part of the uterus and to irradiate pelvic lymph nodes. Maybe some low-risk patients for metastasis into lymph nodes were over-treated by using lymph node boost, but the absence of failure in lymph nodes shows that irradiation of lymph nodes is rational for inoperable stage I and II endometrial cancer patients.
Late radiation toxicity rate of 0-17.3% was reported in LDR brachytherapy series, [3] [4] [5] [6] [7] [8] [9] [10] [11] and 4.6-23% -in HDR brachytherapy series. [12] [13] [14] [15] [16] [17] [18] [19] In this study, grade 1 and 2 late radiation toxicity was observed in 13.8% of patients, but there was no grade 3 or 4 toxicity. We think that the main reason for the absence of G3-4 radiation complications is that no irradiation of the vagina was used in this trial.
Lehoczsky O. et al. reported on 234 stage I patients treated with intrauterine irradiation without vaginal application. 7) There were no serious complications in their series, while 0-24% complication rates have been reported in literature. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] High rectal complication rates were reported by Abayomi O. et al. when using separate vaginal applications delivering 40 Gy to the surface of the upper vagina. Four patients in their series had treatment-related bowel complications requiring colostomy. They concluded that the additional vaginal surface dose should not exceed 20 Gy in patients with no macroscopic tumor spread to the vagina. 29) There were no vagina failures in our series although irradiation of the vagina was not performed.
A variety of methods for brachytherapy of endometrial cancer have been described; none of these methods, however, have been entirely satisfactory. In this study, we used applicator consisting of three channels: one was placed along the central axis of the uterus, and other two curved away from one another into the cornula of the uterus. The longer exposition of the sources in the upper part of the all three channels allowed for a better dose distribution to the fundus uteri and led to achieve higher dose. Low uterine failure rates in this study showed the applicability of the brachytherapy method used in this study. On the other hand, an improvement in tumor control increased late radiation complication rate up to 13.8%. The limitation of this study was that 2-D planning was used, and thus the dose coverage of the outer contour of the uterus was not accurate. Also, it was difficult to spare organs adjacent to uterus such as colon, rectum and bladder from considerable brachytherapy dose. Nowadays this problem can be solved by using sectional image-based brachytherapy with 3-D treatment planning, 30) which was not available at the time when the study was performed.
In conclusion, relatively high DSS results and moderate number of radiation complications in our study showed that HDR brachytherapy with EBRT appears to be an effective and safe treatment for stage I and II medically inoperable endometrial cancer. The results of treatment in patients with stage III endometrial cancer are disappointing, and improvements of treatment strategies for this stage are needed.
